Skip to main content
OpenTrials
Completed

NCT Number: NCT04862975

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana

The purpose of this study is to characterize the pharmacokinetics (PK) of understudied drugs administered to lactating women, receiving antiretroviral drugs per SOC as prescribed by their healthcare provider, and their co-enrolled infants ≤180 days of age who receive maternal breastmilk.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Prospective, single-site, open label, PK and safety study. Co-enrollment of lactating women ≥18 years of age receiving drugs of interest (DOIs) per standard of care (SOC), as prescribed by their healthcare providers, and their infants who receive maternal breastmilk ≤180 days postpartum.

To understand drug transfer into breastmilk and determine subsequent infant exposure, biological samples will be collected from lactating women (blood and breastmilk) and infants (blood). The opportunistic design of this study will allow for a minimal risk study, an expanded enrollment net, evaluation of antiretroviral drugs, and capitalization of procedures performed per SOC to maximize study efficiency and data collection and minimize potential risk to participants. The data collected through this initiative will provide valuable PK, dosing, and safety information for drugs in this vulnerable population in order to inform public health.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Mothers/Infants:

  • Lactating women ≥18 years of age who are receiving at least one DOI per SOC who are ≤180 days postpartum, and their infants (≤180 days of age) who receive maternal breastmilk.
  • Informed consent, according to local IRB/REB/IEC guidelines, prior to any study-related procedures.
  • If the mother is receiving more than one DOI, the mother must have taken all DOIs that she is receiving concomitantly for the 6 doses prior to sample collection.
  • Mother participant is fluent in English or Setswana.
  • Willing to provide at least 1 of the below required samples between the co-enrolled mother/infant pair:
  • Maternal breastmilk
  • Infant blood

Exclusion criteria

Mothers/Infants:

  • Any concomitant condition which, in the opinion of the participant's healthcare provider, the site principal investigator (PI), a research nurse, or designee conducting the study, would preclude participation in the study.
  • Known pregnancy of mother during sample collection.
  • Mother has pumped any breastmilk at all in between the last 6 direct infant feedings prior to sample collection.
  • Infant was fed breastmilk in any manner besides nursing at mother's breast for any of the last 6 feedings prior to sample collection.
  • Previous enrollment on this study.

Treatment and study plan

Dolutegravir

Drug

Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.

Other names: Dolutegravir Sodium, DTG

Lamivudine

Drug

Lamivudine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.

Other names: 3TC

Emtricitabine

Drug

Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.

Other names: FTC

Tenofovir disoproxil fumarate

Drug

Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.

Other names: Tenofovir DF, TDF

Primary outcomes

  1. Drug concentration in maternal plasma

    Time frame: Baseline

    Drug concentration of a DOI in maternal plasma

  2. Drug concentration in maternal breastmilk

    Time frame: Baseline

    Drug concentration of a DOI in maternal breastmilk

  3. Drug concentration in infant plasma

    Time frame: Baseline

    Drug concentration of a DOI in infant plasma

  4. Milk/Plasma ratio

    Time frame: Baseline

    The drug exposure of selected DOIs will be evaluated using milk/plasma ratio

  5. Estimated daily infant dose

    Time frame: Baseline

    The drug exposure of selected DOIs will be evaluated using the estimated daily infant dose

  6. Relative infant dose

    Time frame: Baseline

    The drug exposure of selected DOIs will be evaluated using relative infant dose

  7. Infant/maternal exposure ratio

    Time frame: Baseline

    The drug exposure of selected DOIs will be evaluated using infant/maternal exposure ratio

Other outcomes

  1. PK of selected DOIs in lactating women and breastmilk fed infants as measured by Clearance (CL) or apparent clearance (CL/F).

    Time frame: Baseline

    Clearance (CL) or apparent clearance (CL/F)

  2. PK of selected DOIs in lactating women and breastmilk fed infants as measured by volume of distribution (V) or apparent volume of distribution (V/F)

    Time frame: Baseline

    Volume of distribution (V) or apparent volume of distribution (V/F)

  3. PK of selected DOIs in lactating women and breastmilk fed infants as measured by elimination Half-life (t1/2).

    Time frame: Baseline

    Elimination Half-life (t1/2)

  4. PK of selected DOIs in lactating women and breastmilk fed infants as measured by absorption rate constant (ka).

    Time frame: Baseline

    Absorption rate constant (ka)

  5. PK of selected DOIs in lactating women and breastmilk fed infants as measured by area under the curve (AUC).

    Time frame: Baseline

    Area under the curve (AUC)

  6. PK of selected DOIs in lactating women and breastmilk fed infants as measured by elimination rate constant (kel).

    Time frame: Baseline

    Elimination rate constant (kel)

  7. PK of selected DOIs in lactating women and breastmilk fed infants as measured by maximum concentration (CMAX).

    Time frame: Baseline

    Maximum concentration (CMAX)

  8. PK of selected DOIs in lactating women and breastmilk fed infants as measured by time to reach maximum concentration (TMAX).

    Time frame: Baseline

    Time to reach maximum concentration (TMAX)

  9. Correlation of PK parameters (drug concentration in maternal breastmilk) with maternal BMI

    Time frame: Baseline

    Correlation of drug concentration of each DOI in maternal breastmilk with maternal BMI

  10. Correlation of PK parameters (drug concentration in maternal plasma) with maternal BMI

    Time frame: Baseline

    Correlation of drug concentration of each DOI in maternal plasma with maternal BMI

  11. Correlation of PK parameters (drug concentration in infant plasma) with maternal BMI

    Time frame: Baseline

    Correlation of drug concentration of each DOI in infant plasma with maternal BMI

  12. Correlation of PK parameters (milk/plasma ratio) with maternal BMI

    Time frame: Baseline

    Correlation of milk/plasma ratio of each DOI with maternal BMI

  13. Correlation of PK parameters (estimated daily infant dose) with maternal BMI

    Time frame: Baseline

    Correlation of estimated daily infant dose of each DOI with maternal BMI

  14. Correlation of PK parameters (relative infant dose) with maternal BMI

    Time frame: Baseline

    Correlation of relative infant dose of each DOI with maternal BMI

  15. Correlation of PK parameters (infant/maternal exposure ratio) with maternal BMI

    Time frame: Baseline

    Correlation of infant/maternal exposure ratio for each DOI with maternal BMI

  16. Safety ESIs for infants

    Time frame: Baseline

    Will be collected from the medical record at the time of sample collection

Sponsors and collaborators

Lead sponsor

Duke University

Other

Collaborators

  • The Emmes Company, LLC

Registry information

Acronym: BMS02

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 28, 2021
Registry last updated
Feb 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.